MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Aurinia Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

8.79 -1.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.76

Max

9.05

Pagrindiniai rodikliai

By Trading Economics

Pajamos

22M

23M

Pardavimai

2.6M

62M

P/E

Sektoriaus vid.

27.667

39.564

Pelno marža

37.371

Darbuotojai

130

EBITDA

15M

22M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+7.5% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-119M

1B

Ankstesnė atidarymo kaina

10.36

Ankstesnė uždarymo kaina

8.79

Naujienos nuotaikos

By Acuity

50%

50%

174 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-11 22:19; UTC

Įsigijimai, susijungimai, perėmimai

FCC Approves U.S. Cellular Sale to T-Mobile

2025-07-11 17:28; UTC

Pagrindinės rinkos jėgos

SharpLink Gaming Gains on Ethereum Purchase

2025-07-11 16:57; UTC

Uždarbis

BASF Cuts Outlook on Global Economy Uncertainty

2025-07-11 21:45; UTC

Rinkos pokalbiai

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

2025-07-11 19:46; UTC

Įsigijimai, susijungimai, perėmimai

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

2025-07-11 19:45; UTC

Rinkos pokalbiai

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

2025-07-11 19:05; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

2025-07-11 18:18; UTC

Rinkos pokalbiai

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

2025-07-11 17:35; UTC

Rinkos pokalbiai

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

2025-07-11 17:26; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

2025-07-11 16:53; UTC

Rinkos pokalbiai

Crude Futures Add to Early Gains -- Market Talk

2025-07-11 16:42; UTC

Uždarbis

BASF Cuts Outlook on Global Economic Uncertainty

2025-07-11 16:08; UTC

Rinkos pokalbiai

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

2025-07-11 16:05; UTC

Uždarbis

BASF Will Publish Half-Year Results on July 30

2025-07-11 16:04; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-11 16:04; UTC

Rinkos pokalbiai

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

2025-07-11 16:03; UTC

Uždarbis

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

2025-07-11 16:02; UTC

Uždarbis

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

2025-07-11 16:01; UTC

Uždarbis

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

2025-07-11 16:00; UTC

Uždarbis

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

2025-07-11 15:59; UTC

Uždarbis

BASF Cuts 2025 Earnings View

2025-07-11 15:58; UTC

Uždarbis

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

2025-07-11 15:57; UTC

Uždarbis

BASF 2Q EBIT Before Special Items EUR810M

2025-07-11 15:54; UTC

Uždarbis

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

2025-07-11 15:54; UTC

Uždarbis

BASF 2Q Sales Fell 2.1% on Year

2025-07-11 15:53; UTC

Uždarbis

BASF 2Q Sales EUR15.77B

2025-07-11 15:52; UTC

Uždarbis

BASF: This Was in Line With Consensus Estimates

2025-07-11 15:52; UTC

Uždarbis

BASF 2Q Ebitda Before Special Items EUR1.77B

2025-07-11 15:49; UTC

Uždarbis

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

2025-07-11 15:41; UTC

Rinkos pokalbiai

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

7.5% į viršų

12 mėnesių prognozė

Vidutinis 9.6 USD  7.5%

Aukščiausias 11 USD

Žemiausias 8 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aurinia Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

8.1 / 8.21Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

174 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.